Suppr超能文献

黄芪甲苷在心力衰竭中的最新作用。

An updated role of astragaloside IV in heart failure.

机构信息

Academy of Interdisciplinary Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

School of Pharmacy, Second Military Medical University, Shanghai, China; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.

出版信息

Biomed Pharmacother. 2020 Jun;126:110012. doi: 10.1016/j.biopha.2020.110012. Epub 2020 Mar 23.

Abstract

Heart failure (HF) has become a worldwide public health problem that seriously threatens human's health. Due to "multi-target" effect, traditional Chinese medicine (TCM) has unique advantages in this field. Chinese herb-derived active components would provide valuable candidate compounds for new drug development. Astragaloside IV(AS-IV) is a main effective ingredient of Astragalus membranaceus, a commonly used Chinese patent medicine for the patients with chronic heart failure(CHF). Our aim is to review the recent progresses of AS-IV in HF, and provide potential evidence for its clinical application. Data showed that AS-IV could protect myocardial ischemia, regulate sarcoplasmic reticulum Ca pump, promote angiogenesis, improve energy metabolism, inhibit cardiac hypertrophy and fibrosis, reduce myocardial cell apoptosis, etc, which are direct or indirect involved in the beneficial effects of AS-IV in rodents or cellular models of HF. AS-IV or its derivatives may act as a potential therapeutic drug in the clinical treatment of HF.

摘要

心力衰竭(HF)已成为全球公共卫生问题,严重威胁人类健康。由于“多靶点”效应,中药(TCM)在这一领域具有独特的优势。中药来源的活性成分可为新药开发提供有价值的候选化合物。黄芪甲苷(AS-IV)是黄芪的主要有效成分之一,是治疗慢性心力衰竭(CHF)患者的常用中药。我们的目的是综述 AS-IV 在 HF 中的最新研究进展,为其临床应用提供潜在的依据。研究表明,AS-IV 可以保护心肌缺血,调节肌浆网 Ca 泵,促进血管生成,改善能量代谢,抑制心肌肥厚和纤维化,减少心肌细胞凋亡等,这些都直接或间接涉及 AS-IV 在 HF 啮齿动物或细胞模型中的有益作用。AS-IV 或其衍生物可能成为 HF 临床治疗的一种潜在治疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验